FDA Adverse Event Malfunction Summary report: N

UNKNOWN DELTA VALVE/SHUNT

MDR report key: 7325233 · Received March 8, 2018

Report

Report Number
2021898-2018-00131
Event Type
Malfunction
Date Received
March 8, 2018
Date of Event
November 6, 2017
Report Date
March 27, 2018
Manufacturer
MEDTRONIC NEUROSURGERY
Product Code
JXG
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
AR, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

PLEASE NOTE THAT THIS DATE IS BASED OFF THE DATE OF PUBLICATION OF THE ARTICLE AS THE ACTUAL EVENT DATE WAS NOT PROVIDED. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Additional Manufacturer Narrative · 1

IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

MICHAEL S. GOLINKO, DANIELLE N. ATWOOD, EYLEM OCAL. SURGICAL MANAGEMENT OF CRANIOSYNOSTOSIS IN THE SETTING OF A VENTRICULAR SHUNT: A CASE SERIES AND TREATMENT ALGORITHM. CHILDS NERVOUS SYSTEM 34 (2018). DOI: 10.1007/S00381-017-3648-Y ABSTRACT PURPOSE CEREBROSPINAL FLUID DIVERSION VIA VENTRICULAR SHUNT IS A COMMON TREATMENT FOR HYDROCEPHALUS. CHANGE IN CRANIAL MORPHOLOGY ASSOCIATED WITH A SUTURAL FUSION HAS BEEN TERMED SHUNT-RELATED OR INDUCED CRANIOSYNOSTOSIS (SRC) OR CRANIOCEREBRAL DISPROPORTION (CCD). WE PRESENT A SERIES OF PATIENTS WITH SRC WHO UNDERWENT CRANIAL VAULT REMODELING (CVR) AND OUR TREATMENT ALGORITHM. METHODS THIRTEEN PATIENTS WERE RETROSPECTIVELY REVIEWED WHO HAD SRC AND CVR; 92%OF PATIENTS HAD A VENTRICULOPERITONEAL (VP) SHUNT PLACED FOR LARGELY INTRAVENTRICULAR HEMORRHAGE OF PREMATURITY (69% OF PATIENTS) AT A MEAN AGE OF 2.2 MONTHS. THE SHUNT REVISION RATE WAS 38.4%, AND 54% OF PATIENTS HAD A PROGRAMMABLE SHUNT PLACED INITIALLY. RESULTS THE MEAN AGE AT TIME OF CVR WAS 3.6 YEARS OLD. THE MOST COMMONLY AFFECTED SUTURES (CT CONFIRMED) WERE THE SAGITTAL AND CORONAL SUTURES, WITH THREE PATIENTS EXHIBITING PANCRANIOSYNOSTOSIS. THE MEAN TIME FROM PLACEMENT OF THE SHUNT TO CT EVIDENCE OF SUTURAL FUSION WAS 2.0 YEARS. ABNORMAL HEAD SHAPE WAS NOTED IN ALL 13 PATIENTS; 11 OF THESE ALSO HAD EITHER CHRONIC HEADACHES, PAPILLEDEMA, SEIZURES, OR BEHAVIORAL CHANGES IN THE SETTING OF FUNCTIONAL SHUNT. MEAN FOLLOW-UP AFTER THE INITIAL CVR WAS 3.3 YEARS. NO SHUNT INFECTIONS WERE ATTRIBUTED TO THE CVR. THE FAMILIES OF ALL PATIENTS WERE CONTACTED AND REPORTED IMPROVEMENT IN HEAD SHAPE WITH 60% OF FAMILIES REPORTING IMPROVEMENT IN BEHAVIOR, 75% REPORTED IMPROVEMENT IN HEADACHES, AND 40% REPORTED DECREASE IN SEIZURE FREQUENCY OR INTENSITY. SHUNT SETTING OR TYPE WAS NOT ROUTINELY CHANGED AFTER CVR. CONCLUSIONS OUR THRESHOLD FOR CVR IN SRC IS MET WHEN SHUNT MALFUNCTION HAS BEEN RULED OUT AND THERE ARE (1) RADIOGRAPHIC EVIDENCE OF CRA NIOSYNOSTOSIS, (2) SIGNS OF INCREASED ICP CLINICALLY OR RADIOGRAPHICALLY, AND (3) CRANIAL DYSMORPHISM, I.E., DOLICHOCEPHALY. THE MAJORITY OF CASES OF SRC RESULT IN IMPROVED CRANIAL MORPHOLOGY IN ADDITION TO SOME ABATEMENT OF THE SYMPTOMS OF INCREASED INTRACRANIAL PRESSURE. EARLY INVOLVEMENT OF AN EXPERIENCED CRANIOFACIAL/NEUROSURGICAL TEAM COULD ALLOW FOR EARLY DIAGNOSIS AND INTERVENTION WHICH MAY PREVENT PROGRESSION TO MORE SEVERE DEFORMITIES. SRC IS A COMPLEX ENTITY, WITH MULTIPLE ETIOLOGIES, AND A FUTURE STUDY IS NEEDED. REPORTED EVENTS. A FEMALE WHO WAS IMPLANTED FOR INTRAVENTRICULAR HEMORRHAGE (IVH) HAD BEEN EXPERIENCING THE FOLLOWING ADVERSE SYMPTOMS ASSOCIATED TO THE SETTING OF THE FUNCTIONAL SHUNT: ABNORMAL HEAD SHAPE.

Description of Event or Problem · 1

ADDITIONAL INFORMATION RECEIVED REPORTED THAT THERE WAS NO FURTHER INFORMATION BECAUSE THESE WERE PATIENTS WHO DID NOT RECEIVE A MEDTRONIC SHUNT FOR THE SURGERY DESCRIBED IN THE LITERATURE ARTICLE. IT IS UNCLEAR THE INVOLVEMENT OF THE MEDTRONIC DEVICES SINCE IN THE LITERATURE ARTICLE, THE PATIENTS HAD MEDTRONIC DEVICES.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
166550 UNKNOWN DELTA VALVE/SHUNT SHUNT, CENTRAL NERVOUS SYSTEM AND COMPONENTS JXG MEDTRONIC NEUROSURGERY UNKNOWN-A UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1